PhRMA’s Patient Access Investment: $500 B...

By HEOR Staff Writer

September 30, 2025

Yesterday PhRMA announced steps to boosting patient access to treatments. The announcement showcases the U.S. biopharmaceutical industry’s initiative to enhance patient access and stimulate economic growth. The announcement outlines a remarkable $...
Sanofi Insulin Savings: Your Comprehensive Guide for 2025
The Market Dynamics of Track One Patent Strategy in Pharmaceuticals
Biosimilars Market Trends 2025: Understanding Erosion and Growth
NHS Productivity Gains at Risk: Balancing Innovation and Cost Control
NICE Kidney Cancer Guideline: Enhancing Biopsy Use to Minimize Unnecessary Su...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival
UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic ...
Evolving Strategies in Type 2 Diabetes Management: NICE Guideline Update 2025
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit
Key Decisions on Health Technology Assessment at ACP124: Implications for Rar...